• The FDA has approved Rasonque, a drug for advanced pancreatic cancer that nearly doubles patient survival.
• This treatment, known as daraxonrasib, targets mutated genes fueling tumor growth in 90% of cases.
• Clinical trials showed patients treated with Rasonque had a median survival of 13.2 months versus 6.7 months with chemotherapy.
• Former Senator Ben Sasse reported significant improvements in pain and tumor size while on the drug.
• The one-month supply of Rasonque is priced at approximately $39,800, reflecting its groundbreaking nature.

The U.S. Food and Drug Administration (FDA) recently granted expedited approval to a new treatment for advanced pancreatic cancer, branded as Rasonque and scientifically named daraxonrasib. This groundbreaking drug has shown the potential to nearly double the overall survival rate for patients with this notoriously difficult-to-treat cancer, increasing survival from an average of 6.7 months for standard chemotherapy to 13.2 months for those taking Rasonque, according to Reuters, Le Monde, BBC, CBS News, and NPR.

Rasonque works by inhibiting a mutated protein that drives tumor growth, specifically targeting the KRAS gene mutation, which is present in over 90% of pancreatic cancers. The acceptance of this drug marks a significant advancement as KRAS mutations were previously considered "undruggable" for decades, as noted by CBS News and NPR.

In clinical trials, the drug not only improved survival rates but also demonstrated a better side effect profile compared to traditional chemotherapy, with common side effects including rash, diarrhea, and nausea but a lower incidence of severe effects, as reported by Le Monde and BBC.

The FDA’s approval of Rasonque was expedited, with the agency citing the drug's significant benefits in treating an area with high unmet needs. The approval itself was over six months ahead of the targeted deadline, a move praised by FDA officials as a reflection of their commitment to improving patient outcomes quickly, according to Reuters and CBS News.